Localized striatal delivery of GDNF as a treatment for Parkinson disease
- 27 January 2004
- journal article
- review article
- Published by Springer Nature in Nature Neuroscience
- Vol. 7 (2) , 105-110
- https://doi.org/10.1038/nn1175
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson diseaseNature Medicine, 2003
- Growth-factor gene therapy for neurodegenerative disordersThe Lancet Neurology, 2002
- Recombinant proteins for neurodegenerative diseases: the delivery issueTrends in Neurosciences, 2001
- Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6‐OHDA lesion model depends on the site of administration of the trophic factorEuropean Journal of Neuroscience, 2000
- Sequential Administration of GDNF into the Substantia Nigra and Striatum Promotes Dopamine Neuron Survival and Axonal Sprouting but Not Striatal Reinnervation or Functional Recovery in the Partial 6-OHDA Lesion ModelExperimental Neurology, 2000
- Long‐term protection of the rat nigrostriatal dopaminergic system by glial cell line‐derived neurotrophic factor against 6‐hydroxydopamine in vivoEuropean Journal of Neuroscience, 1998
- GDNF Protection against 6-OHDA: Time Dependence and Requirement for Protein SynthesisJournal of Neuroscience, 1997
- Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson’s DiseaseJournal of Neuroscience, 1996
- Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion.Proceedings of the National Academy of Sciences, 1995
- Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the ratNeuroscience, 1994